bone and mineral disorders in chronic kidney disease parker gregg internal medicine r3
TRANSCRIPT
![Page 1: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/1.jpg)
Bone and Mineral Disorders in Chronic Kidney Disease
Parker GreggInternal Medicine R3
![Page 2: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/2.jpg)
![Page 3: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/3.jpg)
Learning Objectives
List 3 different medications for the treatment of hyperparathyroidism in CKD and how they differ
Differentiate secondary hyperparathyroidism, adynamic bone disease, and other bone/mineral disorders by lab values and clinical presentation
Describe the mechanisms by which bone and mineral disorders develop in CKD
![Page 4: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/4.jpg)
Table of Contents
Monitoring and treatment of bone and mineral disorders in CKD
MKSAP cases to illustrate types of bone and mineral disorders in CKD
How things go so wrong in CKD
Review of normal calcium, phos, PTH, and vitamin D homeostasis
![Page 5: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/5.jpg)
NORMAL CALCIUM, PHOS, PTH, AND VITAMIN D HOMEOSTASIS
![Page 6: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/6.jpg)
Key Points
PTH does everything it can to increase ECF calcium, but to keep phos relatively balanced it wastes phos in the
urine
ECF calcium and vitamin D decrease PTH secretion; phos increases PTH secretion
Vitamin D’s main goal is to increase bone mineralization
ECF calcium comes from guts, bones, and kidneys
![Page 7: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/7.jpg)
Calcium and Phosphate
Homeostasis
![Page 8: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/8.jpg)
Key Points
PTH does everything it can to increase ECF calcium, but to keep phos relatively balanced it wastes phos in the
urine
ECF calcium and vitamin D decrease PTH secretion; phos increases PTH secretion
Vitamin D’s main goal is to increase bone mineralization
ECF calcium comes from guts, bones, and kidneys
![Page 9: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/9.jpg)
Vitamin D Metabolism
Cholecalciferol (D3)
25-hydroxycholecalciferol
1,25-dihydroxycholecalciferol
Increased intestinal absorption of calcium
Liver
Kidney
Gut
Activation PTH
Inhibition
![Page 10: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/10.jpg)
Vitamin D Effects on Calcium and PO4
![Page 11: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/11.jpg)
Key Points
PTH does everything it can to increase ECF calcium, but to keep phos relatively balanced it wastes phos in the
urine
ECF calcium and vitamin D decrease PTH secretion; phos increases PTH secretion
Vitamin D’s main goal is to increase bone mineralization
ECF calcium comes from guts, bones, and kidneys
![Page 12: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/12.jpg)
PTH Effects on Calcium and PO4
Calcium and PO4
via increased
production of
vitamin D Calcium and PO4
PO4
Calcium
![Page 13: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/13.jpg)
Key Points
PTH does everything it can to increase ECF calcium, but to keep phos relatively balanced it wastes phos in the
urine
ECF calcium and vitamin D decrease PTH secretion; phos increases PTH secretion
Vitamin D’s main goal is to increase bone mineralization
ECF calcium comes from guts, bones, and kidneys
![Page 14: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/14.jpg)
Ca Vit D
Parathyroid gland
Parathyroid Hormone Regulation
High calcium and 1,25-OH vit D decrease PTH
secretion
High phos stimulates PTH
PO4
![Page 15: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/15.jpg)
Key Points
PTH does everything it can to increase ECF calcium, but to keep phos relatively balanced it wastes phos in the
urine
ECF calcium and vitamin D decrease PTH secretion; phos increases PTH secretion
Vitamin D’s main goal is to increase bone mineralization
ECF calcium comes from guts, bones, and kidneys
![Page 16: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/16.jpg)
WHEN THINGS START TO GO WRONG
![Page 17: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/17.jpg)
CKD Bone and mineral
disorders
![Page 18: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/18.jpg)
Initiation of CKD-BMD
![Page 19: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/19.jpg)
Decreased GFR
Decreased filtration of phos
Hyperphosphatemia
Hypocalcemia
Increased PTH
Early secondary hyperparathyroidism
maintains normal calcium and phos levels
Initiation of CKD-BMD
![Page 20: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/20.jpg)
Calcium and PO4
Calcium
PO4
Calcium and PO4
via increased
production of
vitamin D
Secondary Hyperparathyroidism
![Page 21: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/21.jpg)
Osteitis fibrosa cystica (High Turnover Bone Disease)
Radiographic sclerosis, cystic bone
lesions, and subperiosteal bone
resorption
Elevated PTH and AlkPhos from high
bone turnover
![Page 22: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/22.jpg)
Osteitis fibrosa cystica (High Turnover Bone Disease)
Brown tumor in the distal ulna
Elevated PTH and AlkPhos from high
bone turnover
![Page 23: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/23.jpg)
Tertiary Hyperparathyroidism
Parathyroid hyperplasia that no longer responds to
calcium
Autonomous secretion of PTH
Hyperplastic gland doesn’t involute
![Page 24: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/24.jpg)
Secondary Hyperparathyroidism (High Turnover Bone
Disease)
Adynamic Bone Disease
(Low Turnover Bone Disease)
Undersuppression of PTH Oversuppression of PTH
![Page 25: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/25.jpg)
PTH Effects on Calcium and PO4
Calcium and PO4
via increased
production of
vitamin D Calcium and PO4
PO4
Calcium
![Page 26: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/26.jpg)
Adynamic Bone Disease (Low Turnover Bone Disease)
Bone Pain Fractures
Vascular Calcification
Hypercalcemia
Low Bone Turnover
![Page 27: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/27.jpg)
![Page 28: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/28.jpg)
Extraosseous Calcification
Vascular Calcification
Increased Mortality
![Page 29: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/29.jpg)
18%
CKD 3-5
19%
Hemodialysis
50%
Peritoneal Dialysis
Adynamic Bone DiseaseNo Adynamic Bone Disease
Adynamic Bone Disease (Low Turnover Bone Disease)
![Page 30: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/30.jpg)
Adynamic Bone Disease (Low Turnover Bone Disease)
Caused by oversuppression of PTH
Therefore…
PTH is
Bone specific AlkPhos is
LOW*
LOW/NORMAL
*PTH <100. Can see in patients with PTH 100-450, but is harder to diagnose.
![Page 31: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/31.jpg)
Disorder Phos Calcium PTH AlkPhos
Secondary Hyperpara-thyroidism
Adynamic Bone Disease
*Adynamic bone disease not excluded in PTH 100-450
Lab Values in CKD-BMD
−/ −/ * −/
![Page 32: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/32.jpg)
Osteomalacia
Vitamin D deficiency
Profound hypocalcemia
Aluminum exposure
![Page 33: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/33.jpg)
Mixed Osteodystrophy
OsteomalaciaHigh or low
turnover bone disease
![Page 34: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/34.jpg)
B2-Microglobulin Amyloidosis(Dialysis-Related Amyloidosis)
![Page 35: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/35.jpg)
B2-Microglobulin Amyloidosis
(Dialysis-Related
Amyloidosis)
![Page 36: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/36.jpg)
MKSAP QUESTIONS
![Page 37: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/37.jpg)
MKSAP Question 1
A 59 year-old woman is evaluated for a 2-week history of right hip pain. She has chronic kidney disease treated with peritoneal dialysis. Medications are epoetin alfa, calcium acetate, calcitriol, and a multivitamin. She has no history of exposure to aluminum-containing medications.
On physical examination, vital signs are normal. There is tenderness over the right lateral trochanter. Internal and external rotation of the hip elicit pain.
![Page 38: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/38.jpg)
Laboratory studies:Phosphorus 5.6 mg/dLCalcium 10.2 mg/dLAlkaline phosphatase 86 U/LIntact PTH 21 pg/mL1,25-dihydroxyvitamin D 52 pg/mL25-hydroxyvitamin D 15 ng/mL
MKSAP Question 1
![Page 39: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/39.jpg)
Plain radiograph of the right hip shows diffuse osteopenia. An area of lucency is seen along the medial aspect of the femoral neck on the right side consistent with a stress fracture.
MKSAP Question 1
![Page 40: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/40.jpg)
Which of the following is most likely the cause of this patient’s bone disease?A. Adynamic bone diseaseB. B2-Microglobulin-associated amyloidosisC. Osteitis fibrosa cysticaD. Osteomalacia
MKSAP Question 1
![Page 41: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/41.jpg)
Osteopenia, fracture, bone pain, serum PTH level <100 pg/mL, and normal AlkPhos level are consistent with adynamic bone disease, which is a leading cause of bone disorders in patients with stage 5 CKD.
Risk factors: advanced age, DM, poor nutrition, and oversuppression of PTH with therapeutic agents
MKSAP Question 1
![Page 42: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/42.jpg)
This patient’s 1,25-dihydroxyvitamin D level >30 pg/mL is consistent with repletion of vitamin D stores with calcitriol. The relatively low 25-hydroxyvitamin D level may be caused by reduced cutaneous synthesis and decreased dietary intake. Decreased hepatic 25-hydroxylation also may occur in patients with CKD.
MKSAP Question 1
![Page 43: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/43.jpg)
Osteitis fibrosa cystica: hyperphosphatemia, hypocalcemia, and 1,25-vitD deficiency -> stimulate PTH secretion -> increase bone turnover. Radiographic sclerosis and subperiosteal bone resorption, elevated PTH, elevated AlkPhos
MKSAP Question 1
![Page 44: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/44.jpg)
B2-microglobulin-associated amyloidosis: cystic bone lesion at the end of long bones that can enlarge over time, resulting in pathologic fractures
Osteomalacia: uncommon. Usually after exposure to aluminum-containing phosphate binders. Usually have elevated serum PTH.
MKSAP Question 1
![Page 45: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/45.jpg)
Adynamic bone disease is a major cause of bone disease in patients with stage 5 CKD and usually manifests as osteopenia, fractures, and bone pain accompanied by a serum PTH level
below 100 pg/mL and a normal alkaline phosphatase level.
Take Home Point
![Page 46: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/46.jpg)
A 33 year-old woman comes for follow up examination for a left fibula fracture due to a fall 1 week ago. She has hypertension and stage 5 CKD treated with home hemodialysis. Medications are lisinopril, sevelamer, epoetin alfa, paricalcitol, and kidney vitamins.
MKSAP Question 2
![Page 47: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/47.jpg)
On physical examination, temperature is normal, blood pressure is 130/70 mmHg, pulse rate is 88/min, and respiration rate is 12/min. BMI is 29. Cardiopulmonary exam is normal. An arteriovenous fistula is present in the left forearm. Except for a cast on her left leg, musculoskeletal examination is normal and reveals no bone pain.
MKSAP Question 2
![Page 48: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/48.jpg)
Laboratory studies:Hemoglobin 10.3 g/dLAlbumin 3.5 g/dLPhosphorus 5.8 mg/dLCalcium 8.4 mg/dLParathyroid hormone 700 pg/mLAlkaline phosphatase 330 U/L
MKSAP Question 2
![Page 49: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/49.jpg)
Which of the following is the most likely cause of this patient’s bone disease?A. Adynamic bone diseaseB. Avascular necrosisC. OsteoporosisD. Secondary hyperparathyroidism
MKSAP Question 2
![Page 50: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/50.jpg)
CKD is associated with progressive alterations in mineral and bone metabolism that can cause bone disease. In patients with ESRD, the kidney’s inability to excrete phosphorus leads to hyperphosphatemia. Loss of kidney function also is associated with 1,25-vitD deficiency. Hyperphosphatemia along with decreased 1,25-vitD levels result in hypocalcemia, which leads to direct stimulation of PTH secretion.
MKSAP Question 2
![Page 51: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/51.jpg)
Furthermore, decreased 1,25-vitD levels cause increased production of PTH. Therefore, bone disease due to secondary hyperparathyroidism, the most common bone pathologic finding seen in patients with ESRD, develops. This patient’s hyperphosphatemia, hypocalcemia, and elevated serum PTH and AlkPhos are consistent with secondary hyperparathyroidism.
MKSAP Question 2
![Page 52: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/52.jpg)
Initiation of CKD-BMD
![Page 53: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/53.jpg)
Adynamic bone disease: hypoparathyroidism caused by excess vitamin D intake and/or calcium loading
Osteoporosis: low bone mass, associated with reduced bone strength and increased risk of fractures. Does not affect the concentrations of serum calcium, phosphorus, or AlkPhos
MKSAP Question 2
![Page 54: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/54.jpg)
Avascular necrosis: transient or permanent lack of blood supply to bone, causing death of bone and bone marrow infarction that results in mechanical failure. Typically present with chronic bone pain and not fracture.
MKSAP Question 2
![Page 55: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/55.jpg)
Bone disease due to secondary hyperparathyroidism commonly occurs
in patients with ESRD and may be associated with elevated serum PTH
and alkaline phosphatase levels, hyperphosphatemia, and
hypocalcemia.
Take Home Point
![Page 56: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/56.jpg)
MONITORING & TREATMENT
![Page 57: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/57.jpg)
Monitoring (KDOQI Guidelines)
Serum Ca and Phos PTH Vitamin D Alkaline
Phosphatase
Stage 3 Q 6-12 months
At least annually
Yearly, replete as
needed--
Stage 4 Q 3-6 months
Q 6-12 months
Yearly, replete as
neededYearly
Stage 5 Q 1-3 months
Q 3-6 months
Yearly, replete as
neededYearly
![Page 58: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/58.jpg)
FIRST INTERVENTION?
54 y/o M with stage 3 CKDCa PO4 PTH
Initial Presentation 8.2 5.8 43
![Page 59: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/59.jpg)
Phosphate Restriction
![Page 60: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/60.jpg)
WHAT’S NEXT?
Ca PO4 PTHInitial Presentation 8.2 5.8 43
6 Months Later 7.8 5.7 50
54 y/o M with stage 3 CKD
![Page 61: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/61.jpg)
Phos Binders
Calcium Phos Binders:- Calcium Carbonate
(Tums)- Calcium Acetate
(Phoslo)
Non-Calcium Phos Binders:- Sevelamer (Renagel,
Renvela)- Lanthanum (PhosRenal)- Less used:
- Aluminum Hydroxide- Magnesium
Hydroxide- Niacin
![Page 62: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/62.jpg)
54 y/o M with stage 3 CKDCa PO4 PTH
Initial Presentation 8.2 5.8 436 Months Later 7.8 5.7 106
WHAT’S ELSE DO YOU CHECK?
![Page 63: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/63.jpg)
Vitamin D Analogs
Nutritional deficiency
Cholecalciferol or ergocalciferol
![Page 64: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/64.jpg)
54 y/o M with stage 4 CKDCa PO4 PTH
Initial Presentation 8.2 5.8 436 Months Later 7.8 5.7 106
1 Year Later 7.0 6.5 648
WHAT’S NEXT?
![Page 65: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/65.jpg)
Vitamin D Analogs
Nutritional deficiency
If PTH still elevated with phos binder and vit D supplementation…
Switch to active vitamin D derivatives:- Calcitriol (1,25-dihydroxyvitamin D)- Paracalcitol (Zemplar) with dialysis
Cholecalciferol or ergocalciferol
![Page 66: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/66.jpg)
54 y/o M with stage 4 CKD
WHAT’S NEXT?
Ca PO4 PTHInitial Presentation 8.2 5.8 43
6 Months Later 7.8 5.7 1061 Year Later 7.0 6.5 6481 Year Later 7.5 5.0 700
![Page 67: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/67.jpg)
Calcimimetic Therapy
Cinacalcet (Sensipar)
Does not act on the GI tract to increase absorption of calcium
![Page 68: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/68.jpg)
Parathyroidectomy
![Page 69: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/69.jpg)
Treatment of Adynamic Bone Disease
STAHP!!
Allow PTH secretion to rise
Decrease serum calcium
Stop vitamin D analogs
Switch to non-calcium phos binders
![Page 70: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/70.jpg)
Learning Objectives
List 3 different medications for the treatment of hyperparathyroidism in CKD and how they differ
Differentiate secondary hyperparathyroidism, adynamic bone disease, and other bone/mineral disorders by lab values and clinical presentation
Describe the mechanisms by which bone and mineral disorders develop in CKD
![Page 71: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/71.jpg)
Take Home Points
Secondary hyperparathyroidism is the end result of the natural progression of the abnormalities set in motion
by hyperphosphatemia
Phos binders, vitamin D analogs, and calcium analogs are all used to treat hyperparathyroidism
Adynamic Bone disease is common, and it is caused by oversuppression of PTH
You (yes, you!) can reason through how CKD-BMD happens
![Page 72: Bone and Mineral Disorders in Chronic Kidney Disease Parker Gregg Internal Medicine R3](https://reader036.vdocument.in/reader036/viewer/2022062421/56649dbe5503460f94ab20d1/html5/thumbnails/72.jpg)
QUESTIONS?